Molecular Endocrinology, Vol 7, 1445-1455, Copyright © 1993 by Endocrine Society

ARTICLES

Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level

PR Srinivas, AS Wagner, LV Reddy, DD Deutsch, MA Leon, AS Goustin and G Grunberger
Center for Molecular Biology, Wayne State University, Detroit, Michigan 48201.

The insulin-dependent tyrosine kinase activity (TKA) of the insulin receptor (IR) plays an essential role in insulin signaling. Thus, dysregulation of IR-TKA might be an important element in the states of insulin resistance. A phosphorylated rat hepatic glycoprotein (pp63) acting as an inhibitor of IR-TK has been described. In search of the human homolog of pp63, we isolated a cDNA clone from a human liver lambda gt11 cDNA library. DNA sequence analysis reveals identity with the mRNA product of a human gene AHSG encoding a serum protein, alpha 2- Heremans Scmid-glycoprotein (alpha 2HSG), with heretofore unknown physiological function. Northern blot analysis demonstrates a 1.8- kilobase mRNA in human liver and HepG2 hepatoma cells. alpha 2HSG, purified from human serum, specifically inhibits insulin-stimulated IR autophosphorylation in vitro and in vivo as well as exogenous substrate tyrosine phosphorylation. alpha 2HSG also inhibits both insulin-induced tyrosine phosphorylation of IRS-1 and the association of IRS-1 with the p85 subunit of phosphatidylinositol-3 kinase in H-35 hepatoma cells. alpha 2HSG inhibits insulin-dependent mitogenesis, but does not affect insulin-stimulated induction of the metabolic enzyme tyrosine aminotransferase. alpha 2HSG does not compete with insulin for binding to IR. Finally, the action of alpha 2HSG is specific toward the IR-TK; its effect does not extend to insulin-like growth factor-I-stimulated TKA. Our results allow us to assign a biochemical function for human alpha 2HSG, namely regulation of insulin action at the IR-TK level.

This article has been cited by other articles:

				N. Stefan, K. Kantartzis, and H.-U. Haring Causes and Metabolic Consequences of Fatty Liver Endocr. Rev., December 1, 2008; 29(7): 939 - 960. [Abstract] [Full Text] [PDF]

				U. D. Akavia and D. Benayahu Meta-analysis and profiling of cardiac expression modules Physiol Genomics, November 12, 2008; 35(3): 305 - 315. [Abstract] [Full Text] [PDF]

				J. H. Ix, C. L. Wassel, A. M. Kanaya, E. Vittinghoff, K. C. Johnson, A. Koster, J. A. Cauley, T. B. Harris, S. R. Cummings, M. G. Shlipak, et al. Fetuin-A and Incident Diabetes Mellitus in Older Persons JAMA, July 9, 2008; 300(2): 182 - 188. [Abstract] [Full Text] [PDF]

				G. Andersen, K. S. Burgdorf, T. Sparso, K. Borch-Johnsen, T. Jorgensen, T. Hansen, and O. Pedersen AHSG Tag Single Nucleotide Polymorphisms Associate With Type 2 Diabetes and Dyslipidemia: Studies of Metabolic Traits in 7,683 White Danish Subjects Diabetes, May 1, 2008; 57(5): 1427 - 1432. [Abstract] [Full Text] [PDF]

				P. Lim, J.-P. Collet, S. Moutereau, N. Guigui, L. Mitchell-Heggs, S. Loric, M. Bernard, S. Benhamed, G. Montalescot, J.-L. D. Rande, et al. Fetuin-A Is an Independent Predictor of Death after ST-Elevation Myocardial Infarction Clin. Chem., October 1, 2007; 53(10): 1835 - 1840. [Abstract] [Full Text] [PDF]

				J. H. Ix, M. G. Shlipak, V. M. Brandenburg, S. Ali, M. Ketteler, and M. A. Whooley Association Between Human Fetuin-A and the Metabolic Syndrome: Data From the Heart and Soul Study Circulation, April 11, 2006; 113(14): 1760 - 1767. [Abstract] [Full Text] [PDF]

				C. Lavebratt, E. Dungner, and J. Hoffstedt Polymorphism of the AHSG gene is associated with increased adipocyte {beta}2-adrenoceptor function J. Lipid Res., October 1, 2005; 46(10): 2278 - 2281. [Abstract] [Full Text] [PDF]

				A. Siddiq, F. Lepretre, S. Hercberg, P. Froguel, and F. Gibson A Synonymous Coding Polymorphism in the {alpha}2-Heremans-Schmid Glycoprotein Gene Is Associated With Type 2 Diabetes in French Caucasians Diabetes, August 1, 2005; 54(8): 2477 - 2481. [Abstract] [Full Text] [PDF]

				X. Ma, J. H. Warram, V. Trischitta, and A. Doria Genetic Variants at the Resistin Locus and Risk of Type 2 Diabetes in Caucasians J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4407 - 4410. [Abstract] [Full Text] [PDF]

				S. T. Mathews, G. P. Singh, M. Ranalletta, V. J. Cintron, X. Qiang, A. S. Goustin, K.-L. C. Jen, M. J. Charron, W. Jahnen-Dechent, and G. Grunberger Improved Insulin Sensitivity and Resistance to Weight Gain in Mice Null for the Ahsg Gene Diabetes, August 1, 2002; 51(8): 2450 - 2458. [Abstract] [Full Text] [PDF]

				C. Menzaghi, N. Plengvidhya, X. Ma, J. H. Warram, S. E. Shoelson, and A. Doria COMMENT: Genetic Variability in Insulin Action Inhibitor Ikk{beta} (IKBKB) Does Not Play a Major Role in the Development of Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1894 - 1897. [Abstract] [Full Text] [PDF]

				H. Chen, P. R. Srinivas, L.-N. Cong, Y. Li, G. Grunberger, and M. J. Quon {alpha}2-Heremans Schmid Glycoprotein Inhibits Insulin-Stimulated Elk-1 Phosphorylation, But Not Glucose Transport, in Rat Adipose Cells Endocrinology, October 1, 1998; 139(10): 4147 - 4154. [Abstract] [Full Text] [PDF]

				W. Jahnen-Dechent, T. Schinke, A. Trindl, W. Muller-Esterl, F. Sablitzky, S. Kaiser, and M. Blessing Cloning and Targeted Deletion of the Mouse Fetuin Gene J. Biol. Chem., December 12, 1997; 272(50): 31496 - 31503. [Abstract] [Full Text] [PDF]

				P. Nawratil, S. Lenzen, J. Kellermann, H. Haupt, T. Schinke, W. Muller-Esterl, and W. Jahnen-Dechent Limited Proteolysis of Human alpha 2-HS Glycoprotein/Fetuin. EVIDENCE THAT A CHYMOTRYPTIC ACTIVITY CAN RELEASE THE CONNECTING PEPTIDE J. Biol. Chem., December 6, 1996; 271(49): 31735 - 31741. [Abstract] [Full Text] [PDF]